Inhibitory effects of sulfonylureas and non‐steroidal anti‐inflammatory drugs on <i>in vitro</i> metabolism of canagliflozin in human liver microsomes

Algeelani, Sara; Alkhelb, Dalal; Greenblatt, David J.

doi:10.1002/bdd.2120

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Separation of glucuronides of CANA was also performed in the study of Algeelani et al [ 39 ], using a HPLC method on a Waters μBondaPak C18 column (3.9 × 300 mm) with fluorescence detection. The elution was isocratic, with the mobile phase at pH 3.2 consisting of ACN and 20 mM phosphate buffer (55:45, v / v ) with a flow rate of 1 mL/min.…”

Section: Gliflozins (Sglt2 Inhibitors)mentioning

confidence: 99%

Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins

Gumieniczek

Berecka‐Rycerz

2023

Biomedicines

View full text Add to dashboard Cite

The drug metabolism and drug degradation pathways may overlap, resulting in the formation of similar constituents. Therefore, the metabolism data can be helpful for deriving safe levels of degradation impurities and improving the quality of respective pharmaceutical products. The present article contains considerations on possible links between metabolic and degradation pathways for new antidiabetic drugs such as glutides, gliflozins, and gliptins. Special attention was paid to their reported metabolites and identified degradation products. At the same time, many interesting analytical approaches to conducting metabolism as well as degradation experiments were mentioned, including chromatographic methods and radioactive labeling of the drugs. The review addresses the analytical approaches elaborated for examining the metabolism and degradation pathways of glutides, i.e., glucagon like peptide 1 (GLP-1) receptor agonists, and gliflozins, i.e., sodium glucose co-transporter 2 (SGLT2) inhibitors. The problems associated with the chromatographic analysis of the peptide compounds (glutides) and the polar drugs (gliflozins) were addressed. Furthermore, issues related to in vitro experiments and the use of stable isotopes were discussed.

show abstract

Section: Gliflozins (Sglt2 Inhibitors)mentioning

confidence: 99%

Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins

Gumieniczek

Berecka‐Rycerz

2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Similarly, inhibitors of UGT enzymes (e.g. arbidol, mefenamic acid and niflumic acid) increase the plasma levels of CNZ, which may result in hypoglycemic conditions (Algeelani, Alkhelb, & Greenblatt, 2018). Therefore, it is important to monitor the plasma concentration and pharmacokinetic profile of CNZ during its therapeutic treatment.…”

Section: Introductionmentioning

confidence: 99%

Quantitative determination of canagliflozin in human plasma samples using a validated HPTLC method and its application to a pharmacokinetic study in rats

Alam

Iqbal

Foudah

et al. 2020

Biomedical Chromatography

View full text Add to dashboard Cite

Canagliflozin (CNZ) is the first sodium-glucose co-transporter-2 inhibitor approved for treatment of type 2 diabetes mellitus. In the proposed work, a sensitive, rapid and validated high-performance thin-layer chromatography (HPTLC) method was established for the estimation of CNZ in human plasma for the first time. HPTLC analysis of CNZ and internal standard (sildenafil) was performed on glass coated silica gel 60 F 254 HPTLC plates using a binary mixture of chloroform-methanol 9:1 (%, v/v) as the mobile phase. Densitometric detection was done at 295 nm. Retardation factor values were obtained as 0.22 and 0.52 for the CNZ and the IS, respectively. The linearity range of CNZ was obtained as 200-3,200 ng/ml. A simple protein precipitation method was used for the extraction of analyte from plasma using methanol. The proposed HPTLC technique was validated for linearity, accuracy, precision and robustness. The proposed HPTLC technique was successfully utilized for the assessment of pharmacokinetic profile of CNZ in rats after oral administration. After oral administration, the peak plasma concentration of CNZ was obtained as 1458.01 ng/ml in 2 h. The proposed HPTLC method could be applied to the study of the pharmacokinetic profile of pharmaceutical formulations containing CNZ.

show abstract

Antidiabetic Drug Interactions

Kelleci Celik

2023

Current Perspective on Diabetes Mellitus in Clinical Sciences

View full text Add to dashboard Cite

Antidiabetic drug interactions pose significant challenges in the management of diabetes mellitus. These interactions can occur between different classes of antidiabetic medications or between antidiabetic drugs and other medications used to treat comorbid conditions. They may affect drug efficacy or safety by altering drug metabolism, absorption, or excretion. Common interactions include sulfonylureas, which can potentiate hypoglycemia when combined with other drugs that affect glucose levels. Similarly, medications such as corticosteroids or certain antibiotics can impair glucose control in diabetic patients. Clinicians must carefully monitor and adjust medication regimens to minimize these interactions and optimize therapeutic outcomes for patients with diabetes.

show abstract

Inhibitory effects of sulfonylureas and non‐steroidal anti‐inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes

Cited by 3 publications

References 25 publications

Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins

Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins

Quantitative determination of canagliflozin in human plasma samples using a validated HPTLC method and its application to a pharmacokinetic study in rats

Antidiabetic Drug Interactions

Contact Info

Product

Resources

About